A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Study consists of two main parts to explore tacabrutideg recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)
Inclusion Criteria
- Confirmed diagnosis (per World Health Organization (WHO) guidelines, unless otherwise noted) of one of the following: Marginal Zone Lymphoma (MZL), R/R follicular lymphoma (FL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL), Waldenström macroglobulinemia (WM), R/R diffuse large B-cell lymphoma (DLBCL), or Richter's transformation to DLBCL.
- Participants who have previously received a covalently-binding Bruton´s tyrosine kinase (BTK) inhibitor (BTKi) in any line of therapy must have received treatment with the BTK inhibitor for ≥ 8 weeks (unless reason for discontinuation is intolerance).
- For dose-finding and dose-expansion, participants who had previously received a covalently-binding BTK inhibitor as monotherapy or in combination with other anticancer agents are eligible for the study if they meet any of the following criteria: discontinued the previous BTK inhibitor due to disease progression, experienced disease progression after completing treatment with a BTK inhibitor or discontinued the BTK inhibitor due to toxicity or intolerance.
- Measurable disease by radiographic assessment or serum IgM level (WM only)
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2
- Participants enrolling in the dose finding phase of the study may be previously treated with a BTKi or may be naïve to BTKi therapy depending on the diagnosis and country of enrollment; participants with MCL enrolling in the expansion cohorts (Phase 2) must have been treated with a BTKi in a prior line of therapy; CLL/SLL participants, in addition to being treated with a BTKi in a prior line of therapy, must also have received a Bcl-2 inhibitor in a prior line of therapy as well (Phase 2).
Exclusion Criteria
- Prior malignancy (other than the disease under study) within the past 2 years, except in situ malignancies that have been curatively resected, localized breast cancer treated with curative intent with no evidence of breast active disease for more than 3 years and receiving adjuvant hormonal therapy, localized Gleason score ≤ 6 prostate cancer undergoing observation or treatment with androgen depravation, or any other cancer treated with curative intent, not on adjuvant treatment, and in the opinion of the investigator is unlikely to recur.
- Requires ongoing systemic treatment for any other malignancy
- Requires ongoing systemic (defined as ≥ 10 mg/day of prednisone or equivalent) corticosteroid treatment.
- Current or history of central nervous system involvement including the brain, spinal cord, leptomeninges, and cerebrospinal fluid (as documented by imaging, cytology, or biopsy) by B-cell malignancy, regardless of whether participants had received treatment for central nervous system disease
- Known active plasma cell neoplasm, prolymphocytic leukemia, T-cell lymphoma, Burkitt lymphoma, acquired immunodeficiency syndrome (AIDS)-related B-cell lymphoma, Castleman disease, post-transplant lymphoproliferative disorders, hairy cell leukemia, germinal center B-cell (GCB), DLBCL, EBV+ DLBCL NOS, primary DLBCL of the central nervous system (CNS), primary cutaneous DLBCL - leg type, DLBCL associated with chronic inflammation, primary mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, ALK+ large B-cell lymphoma, primary effusion lymphoma, high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, high-grade B-cell lymphoma - NOS, B-cell lymphoma unclassifiable with features intermediate between DLBCL and classical Hodgkin lymphoma, or history of or currently suspected transformation of an indolent lymphoma to an aggressive histology (except for participants with Richter Transformation to DLBCL are eligible for Part 1a, 1c, or Phase 2 and participants with history of follicular lymphoma transforming to non-GCB DLBCL who are eligible for Part 1a, 1c, or Phase 2). Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT05006716.
Locations matching your search criteria
United States
Alabama
Birmingham
Arizona
Tucson
California
La Jolla
Los Angeles
Palo Alto
Florida
Jacksonville
Tampa
Iowa
Iowa City
Massachusetts
Boston
Michigan
Detroit
Minnesota
Rochester
New York
Buffalo
New York
Texas
Houston
Virginia
Richmond
Washington
Seattle
A B-cell malignancy is a type of cancer that starts in white blood cells called B-cells.
These cancers can affect the lymph nodes, bone marrow, blood, spleen, and other organs.
Examples of these cancers include chronic lymphocytic leukemia/small lymphocytic
lymphoma, marginal zone lymphoma, follicular lymphoma, Waldenström macroglobulinemia,
mantle cell lymphoma, and diffuse large B cell lymphoma.
Tacabrutideg is a type of medicine called a BTK degrader. BTK (Bruton's tyrosine kinase)
is a protein that helps cancer cells survive. Tacabrutideg is designed to attach to the
BTK protein and tag it for removal, so that the body's own cellular "clean-up" system
breaks it down and clears it away. When more BTK is removed from the body, it interferes
with the signals needed for the cancer cells to multiply and survive and may also reduce
the chance of the cancer becoming resistant to treatment.
The purpose of this study is to test whether tacabrutideg is safe and if it can treat
B-cell malignancies. The main goals are to ensure the drug is safe by monitoring side
effects and to understand how well patients respond to the treatment and whether their
cancers shrink or disappear.
This study consists of two parts: dose escalation and dose expansion. During the dose
escalation part, the study doctors will test different doses of the study drug to find
the recommended dose that people can take without having serious side effects. During the
dose expansion part, the study doctors will test the study drug in a larger number of
people using the dose or doses identified from dose escalation. The study is open label,
which means that the participants and the study doctors will know what treatment is
received.
This study will enroll approximately 689 participants with B-cell malignancies at
multiple centers worldwide.
The overall time to participate in this study is approximately 3 years. Participants will
make regular visits to the clinic for treatment, health checks, blood tests, and tumor
and imaging tests.
Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some
of our older studies were sponsored under the name BeiGene, you may see both names used
for this study on this website.
Trial PhasePhase I/II
Trial Typetreatment
Lead OrganizationBeOne Medicines
- Primary IDBGB-16673-101
- Secondary IDsNCI-2022-01959, 2022-502157-33-00
- ClinicalTrials.gov IDNCT05006716